FENASO FENASO SOLICON SOLICON SOLICON SOLICON SOLICON SOLICON VESIWEL VESIWEL VESIWEL VESIWEL VESIWEL VESIWEL SOLCINA

Dose: 5 to 10 mg
Single Dose: 7.5 (7.5)
Frequency: 24 hourly
Route: PO
Instructions: It can be administered with or without food. In patients with sever renal impairment (CLcr

belongs to Isoquinoline Butane Dioic Acid. It belongs to Cholinergic muscarinic antagonist pharmacological group on the basis of mechanism of action. The Molecular Weight of Solifenacin succinate is 480.50.

Solifenacin succinate is contraindicated in conditions like Narrow-angle glaucoma,Urinary retention,Urinary retention,Gastric retention,Hypersensitivity to any component of product.

The severe or irreversible adverse effects of Solifenacin succinate, which give rise to further complications include Angioneurotic edema, Intestinal obstruction, Respiratory depression.The signs and symptoms that are produced after the acute overdosage of Solifenacin succinate include Disorientation, Vomiting, Tachycardia, Blurred vision, Dry mouth, Urinary retention, Confusion, Respiratory depression, Ataxia, Respiratory depression, Angioedema, Tremor, Mydriasis, Agitation, Photophobia, Memory disturbance, Euphoria, Peripheral edema, Dry skin.The symptomatic adverse reactions produced by Solifenacin succinate are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Nausea, Vomiting, Constipation, Abdominal pain, Dry mouth, Blurred vision, Peripheral edema, Dyspepsia, Urinary retention, Dry eye.

Solifenacin succinate is primarily indicated in conditions like Urinary frequency and incontinence.

Solifenacin succinate is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementKetoconazolesolifenacin succinate is a CYP3A4 substrate , while the ketoconazole is potent CYP3A4 inhibitor so ketoconazole may increase Cmax and AUC of solifenacin succinate by 1.5 and 2.7 foldit is recommended not to exceed a 5mg daily dose of solifenacin succinate when co administrered with ketonconazole or other potent CYP3A4 inhibitorsVORICONAZOLEVoriconazole may increase the serum concentration of solifenacin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Paediatrics, Pregnant Mothers, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tablet Store Between 15°C-30°C.

Incase of angioedema, if involvement of the tongue, hypopharynx, or larynx occurs, solifenacin should be promptly discontinued and appropriate therapy and/or measures necessary to ensure a patent airway should be promptly provided. Administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of urinary retention. Use with caution in patients with decreased gastrointestinal motility, narrow-angle glaucoma, reduced renal function, reduced hepatic function. Its doses greater than 5 mg are not recommended in patients with severe renal impairment (CLcr